Abstract |
The disposition of mesalazine from the azo compounds sulphasalazine and olsalazine ( Dipentum) and from the slow-release mesalazine drugs Pentasa, Asacol, and Salofalk was studied in 20 patients with inflammatory bowel disease. Ten of them had diarrhoea, and 10 had normal stools. On the last 2 days of a 7-day maintenance treatment with each of the study drugs urine and faeces were collected for determination of mesalazine, acetyl- mesalazine, and unsplit azo compound. In patients with and without diarrhoea the urinary and the faecal excretion of acetyl- mesalazine was lowest during treatment with olsalazine. The proportion of acetyl- mesalazine in faeces was highest during treatment with Pentasa in both groups. The presence of diarrhoea was associated with a decrease in the proportion of acetyl- mesalazine in faeces during treatment with all drugs, not significant only for Pentasa. The proportion of unsplit azo compound in faeces increased in the case of diarrhoea to almost 50%. It is concluded that in patients with inflammatory bowel disease diarrhoea substantially influences the disposition from all these drugs except Pentasa.
|
Authors | M C Rijk, A van Schaik, J H van Tongeren |
Journal | Scandinavian journal of gastroenterology
(Scand J Gastroenterol)
Vol. 27
Issue 10
Pg. 863-8
(Oct 1992)
ISSN: 0036-5521 [Print] England |
PMID | 1359629
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Aminosalicylic Acids
- Delayed-Action Preparations
- Drug Carriers
- Sulfasalazine
- Mesalamine
- olsalazine
|
Topics |
- Adult
- Aged
- Aminosalicylic Acids
(chemistry, pharmacokinetics, therapeutic use, urine)
- Delayed-Action Preparations
(standards)
- Diarrhea
(etiology)
- Drug Carriers
- Feces
(chemistry)
- Female
- Gastrointestinal Transit
- Humans
- Inflammatory Bowel Diseases
(complications, drug therapy, urine)
- Male
- Mesalamine
- Middle Aged
- Sulfasalazine
(therapeutic use)
|